查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080408

焦慮症治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、病患類型、適應症及分銷管道分類）

Anxiety Drugs Market by Drug Class, Route Of Administration, Patient Type, Indication, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，焦慮症治療市場將成長至 301.1 億美元，複合年成長率為 9.16%。

主要市場統計數據
基準年 2025 162.9億美元
預計年份：2026年 177.3億美元
預測年份 2032 301.1億美元
複合年成長率 (%) 9.16%

根據世界衛生組織（世衛組織）的數據，全球約有3.01億人患有焦慮症，焦慮症藥物仍是全球精神健康治療市場的核心組成部分。支撐這項需求的因素包括疾病負擔沉重、基層醫療篩檢加大、人們對精神健康的認知不斷提高，以及選擇性血清素再回收抑制劑（SSRIs）、正腎上腺素再回收抑制劑（SNRIs）、苯二氮平類藥物、丁螺環酮、 BETA阻斷劑和輔助藥物等藥物療法的持續使用。

在臨床實務中，選擇性血清素再攝取抑制劑（SSRIs）和選擇性血清素和去甲腎上腺素再攝取抑制劑（SNRIs）仍是治療整體焦慮症、恐慌症、社交焦慮症及相關疾病的首選第一線長期治療藥物。另一方面，由於苯二氮平類藥物存在依賴性、鎮靜作用、戒斷症狀和濫用風險，其使用越來越受到限制，通常僅限於短期使用或在嚴密監督下使用。這種平衡影響著品牌藥和非專利整體焦慮症藥物的產品定位、處方趨勢、保險公司審核、藥物安全監測重點以及生命週期策略。

焦慮症治療領域發生的變革性變化

焦慮症藥物治療領域正從抑制症狀轉向更安全、更個人化、更全面的治療。處方醫生優先考慮藥物的長期耐受性、低濫用風險、快速起效、減少性功能障礙、減少藥物交互作用以及與心理治療和數位化心理健康干預措施的兼容性。這些優先事項正在影響成熟市場和新興市場的開發平臺和商業策略。

人工智慧（AI）的累積影響

人工智慧（AI）正對藥物發現、臨床開發、安全性監測以及焦慮症治療的患者支持等領域產生累積影響。在研發領域，AI驅動的標靶辨識、分子建模、文獻挖掘和生物標記分析等技術，使研究團隊能夠更有效率地篩檢化合物，並探索傳統單胺通路以外的新型作用機制。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

北美地區仍然是焦慮症藥物的主要市場，這得益於其較高的診斷率、廣泛的保險覆蓋、精神科和基層醫療領域成熟的處方途徑以及較高的學名藥普及率。美國尤其重要，因為焦慮症是最常見的精神疾病之一，並且有全國性的監測和治療指南支持。另一方面，在加拿大，優先考慮精神健康的公共衛生政策正在推動改善藥物取得、謹慎用藥和基於指南的用藥。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團與北約

在東協地區，精神健康知識的進步、私人醫療網路的擴張以及遠端醫療的普及，正在推動對價格合理的學名藥和利用數位技術治療焦慮症的需求。海灣合作理事會（GCC）國家正在大力投資醫療轉型、數位醫療、專科醫療服務和國家精神衛生項目，從而為高品質治療、醫院合作和社區患者支持模式創造了機會。

來自主要焦慮症治療市場關鍵國家的洞察

由於民眾對焦慮症的認知度高、基層醫療中處方廣泛、遠程精神科診療的引入以及對選擇性血清素再攝取抑製劑（SSRI）、選擇性血清素和去甲腎上腺素再攝取抑製劑（SNRI）以及嚴格控制的短期抗焦慮藥物的強勁需求，美國在焦慮症藥物的使用方面處於領先地位。加拿大則強調公共醫療保健的普及、心理健康計劃和謹慎用藥，而墨西哥和巴西預計將透過私人醫療保健、零售藥局管道、都市區心理健康服務的擴張以及對經濟實惠的學名藥的需求成長而實現成長。

為焦慮症藥物產業的領導者提供的實用建議

產業領導者應優先研發差異化的焦慮症治療方案，這些方案應具備起效迅速、療效持久、耐受性良好、停藥難度低以及依賴性低等特點。此外，研發策略必須滿足患者的實際需求，包括憂鬱症、失眠、藥物濫用風險、慢性疾病、治療順從性等憂鬱症。企業應加強其真實世界證據項目，以證明藥物在不同患者群體中的依從性、復發率降低、功能改善、對醫療資源的影響以及安全性。

調查方法

本執行摘要採用二手調查方法編寫，並整合了公開可用的可靠來源，包括世界衛生組織 (WHO)、國家衛生機構和監管機構的指導、同行評審的臨床資訊來源、處方指南、藥物警戒材料以及對主要地區市場進入的觀察。

結論：抗焦慮藥物的策略性展望

在未被滿足的需求、後疫情時代對心理健康的需求、安全性期望以及數位化醫療模式重塑治療路徑的背景下，抗焦慮藥物市場正在不斷演變。儘管現有藥物類別仍將構成治療的基礎，但競爭優勢正轉向更安全的作用機制、更精準的患者篩選、更強力的用藥依從性支持以及整合的藥物管理。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：焦慮症治療市場：依藥物類別分類

  • 苯二氮平類藥物
    • Alprazolam
    • 氯硝西泮
    • Diazepam
    • Lorazepam
  • BETA阻斷劑
  • 丁螺環酮
  • 選擇性血清素再回收抑制劑
    • escitalopram
    • Fluoxetine
    • 帕羅西汀
    • 舍曲林
  • 正腎上腺素再回收抑制劑
    • Duloxetine
    • 文拉法辛

第8章：焦慮症治療市場：依給藥途徑分類

  • 注射
    • 肌肉內部
    • 靜脈
  • 鼻噴霧
  • 口服
    • 膠囊
    • 液體
    • 藥片
  • 經皮給藥

第9章：焦慮症治療市場：依患者類型分類

  • 成人
  • 老年人
  • 兒童

第10章：焦慮症治療市場：依適應症分類

  • 整體焦慮症（GAD）
  • 強迫症（OCD）
  • 恐慌症
  • 創傷後壓力症候群（PTSD）
  • 社交焦慮症（SAD）

第11章：焦慮症治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：焦慮症治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：焦慮症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：焦慮症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Amorsa Therapeutics Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Avineuro Pharmaceuticals, Inc.
  • Azevan Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.
  • Bionomics Limited
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Huahai Pharmaceutical Co. Ltd.
  • Intra-Cellular Therapies Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Olainfarm
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Swisschem Healthcare
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-434CCDA05209

The Anxiety Drugs Market is projected to grow by USD 30.11 billion at a CAGR of 9.16% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.29 billion
Estimated Year [2026] USD 17.73 billion
Forecast Year [2032] USD 30.11 billion
CAGR (%) 9.16%

Anxiety drugs remain a core segment of the global mental health therapeutics landscape as anxiety disorders affect an estimated 301 million people worldwide, according to the World Health Organization. Demand is supported by high disease burden, broader screening in primary care, expanding mental health awareness, and sustained use of pharmacologic therapies such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, benzodiazepines, buspirone, beta blockers, and adjunctive agents.

Clinical practice continues to favor SSRIs and SNRIs as first-line long-term treatment options for generalized anxiety disorder, panic disorder, social anxiety disorder, and related conditions, while benzodiazepines are increasingly reserved for short-term or carefully monitored use because of dependence, sedation, withdrawal, and misuse risks. This balance is shaping product positioning, prescribing behavior, payer review, pharmacovigilance priorities, and lifecycle strategies across branded and generic anxiety medications.

Transformative Shifts in the Anxiety Treatment Landscape

The anxiety drugs landscape is shifting from symptom suppression toward safer, more personalized, and integrated care. Prescribers are emphasizing long-term tolerability, lower abuse potential, faster onset, reduced sexual dysfunction, fewer drug-drug interactions, and compatibility with psychotherapy and digital mental health interventions. These priorities are influencing development pipelines and commercial strategies in both established and emerging markets.

Regulatory scrutiny around controlled substances, especially benzodiazepines, is also changing utilization patterns through tighter monitoring, prescribing limits, and patient-risk evaluation. At the same time, the post-pandemic rise in anxiety symptoms has increased demand for accessible treatment, creating opportunities for telepsychiatry-enabled prescribing, pharmacy-led adherence support, measurement-based care, and evidence-based digital therapeutics that complement medication management.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across anxiety drug discovery, clinical development, safety surveillance, and patient support. In research, AI-enabled target identification, molecular modeling, literature mining, and biomarker analysis are helping teams screen compounds more efficiently and explore novel mechanisms beyond traditional monoamine pathways.

In commercial and clinical operations, AI is improving patient stratification, adverse-event monitoring, adherence prediction, signal detection, and real-world evidence generation. Large language model-enabled clinical documentation, AI triage, and remote monitoring may reduce care bottlenecks and support earlier intervention, but industry leaders must address bias, data privacy, explainability, clinical validation, and regulatory oversight before AI can be trusted at scale in psychiatric drug decision-making.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America remains a leading region for anxiety drugs due to high diagnosis rates, broad insurance coverage, established psychiatric and primary care prescribing pathways, and strong generic penetration. The United States is especially important because anxiety disorders are among the most common mental health conditions, supported by national surveillance and treatment guidelines, while Canada's public health focus on mental wellness supports access initiatives, cautious prescribing, and guideline-based medication use.

Europe benefits from mature healthcare systems, strong pharmacovigilance standards, and clear prescribing controls, particularly across the European Union, where evidence-based assessment, reimbursement review, and controlled-substance oversight influence adoption. Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and ASEAN economies invest in mental health awareness, telemedicine, primary care integration, and broader access to psychiatric care. Latin America is gaining momentum through Brazil and Mexico, where retail pharmacy channels, private healthcare expansion, and generic availability support use, although affordability and specialist availability remain constraints. The Middle East and Africa show rising recognition of anxiety disorders, with GCC countries moving faster due to healthcare modernization, digital health investment, and specialist service expansion, while many African markets still face infrastructure gaps, medicine availability challenges, and stigma-related barriers.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7 & NATO

Within ASEAN, improving mental health literacy, expanding private healthcare networks, and wider telehealth adoption are increasing demand for affordable generics and digitally supported anxiety care. The GCC is investing heavily in healthcare transformation, digital health, specialist services, and national mental health programs, creating opportunities for premium therapies, hospital partnerships, and localized patient-support models.

The European Union is shaped by harmonized safety standards, health technology assessment discipline, pricing pressure, pharmacovigilance requirements, and a strong preference for evidence-based prescribing. BRICS markets provide scale and long-term volume potential, especially in China, India, and Brazil, but require pricing discipline, local regulatory expertise, and strategies suited to diverse reimbursement and access conditions. G7 countries continue to drive innovation, clinical standards, guideline development, and reimbursement expectations. NATO member markets overlap significantly with high-income healthcare systems, where supply resilience, controlled-substance monitoring, medicine security, and mental health workforce capacity are strategic priorities.

Key Country Insights Across Major Anxiety Drug Markets

The United States leads anxiety drug utilization through high awareness, extensive primary care prescribing, telepsychiatry adoption, and strong demand for SSRIs, SNRIs, and carefully monitored short-term anxiolytics. Canada emphasizes public health access, mental wellness initiatives, and cautious prescribing, while Mexico and Brazil offer growth through expanding private care, retail pharmacy channels, urban mental health services, and demand for cost-effective generics.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show mature use of antidepressant-based anxiety treatment, supported by clinical guidelines, reimbursement frameworks, and pharmacovigilance systems. Russia remains a distinct market with local regulatory, access, and prescribing dynamics. China and India represent high-volume opportunities as mental health services expand, stigma gradually declines, and digital health channels improve reach, while Japan and South Korea emphasize quality, safety, aging-population considerations, and careful medication management. Australia combines strong mental health awareness with integrated primary care, public mental health initiatives, and telehealth adoption, supporting structured access to pharmacologic and behavioral treatment options.

Actionable Recommendations for Anxiety Drug Industry Leaders

Industry leaders should prioritize differentiated anxiety therapies with faster onset, durable efficacy, strong tolerability, fewer discontinuation challenges, and lower dependence risk. Development strategies should also address real-world patient needs such as comorbid depression, insomnia, substance-use risk, chronic disease, and treatment adherence. Companies should strengthen real-world evidence programs that demonstrate adherence, relapse reduction, functional improvement, health-resource impact, and safety in diverse populations.

Commercial teams should align portfolio strategy with regional access realities by pairing branded innovation with high-quality generics where appropriate. Partnerships with telehealth providers, behavioral health networks, pharmacy systems, and AI-enabled adherence tools can improve patient engagement and continuity of care, while controlled-substance compliance, pharmacovigilance, transparent patient education, and responsible promotion should remain central to risk management.

Research Methodology

This executive summary is developed using a secondary-research-led methodology that synthesizes publicly available and authoritative sources, including the World Health Organization, national health agencies, regulatory guidance, peer-reviewed clinical literature, prescribing guidelines, pharmacovigilance resources, and market access observations across major regions.

The analysis emphasizes verified disease-burden indicators, treatment standards, regulatory direction, digital health adoption, medication safety considerations, and competitive dynamics without relying on market estimation, market sizing, market share, or market forecasting. Insights are cross-checked for consistency across clinical, commercial, and policy sources to support practical interpretation for pharmaceutical manufacturers, investors, healthcare providers, and market strategy teams.

Conclusion: Strategic Outlook for Anxiety Drugs

The anxiety drugs market is evolving as unmet need, post-pandemic mental health demand, safety expectations, and digital care models reshape treatment pathways. Established drug classes will continue to anchor therapy, but competitive advantage is moving toward safer mechanisms, better patient selection, stronger adherence support, and integrated medication management.

Organizations that combine clinical differentiation, regional access discipline, AI-enabled evidence generation, and responsible prescribing frameworks will be best positioned to build durable relevance. The next phase of the anxiety drugs landscape will reward strategies that address both symptom relief and long-term patient functioning while meeting rising expectations for safety, access, and evidence-based care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anxiety Drugs Market, by Drug Class

  • 7.1. Benzodiazepine
    • 7.1.1. Alprazolam
    • 7.1.2. Clonazepam
    • 7.1.3. Diazepam
    • 7.1.4. Lorazepam
  • 7.2. Beta Blocker
  • 7.3. Buspirone
  • 7.4. Selective Serotonin Reuptake Inhibitor
    • 7.4.1. Escitalopram
    • 7.4.2. Fluoxetine
    • 7.4.3. Paroxetine
    • 7.4.4. Sertraline
  • 7.5. Serotonin Norepinephrine Reuptake Inhibitor
    • 7.5.1. Duloxetine
    • 7.5.2. Venlafaxine

8. Anxiety Drugs Market, by Route Of Administration

  • 8.1. Injection
    • 8.1.1. Intramuscular
    • 8.1.2. Intravenous
  • 8.2. Nasal Spray
  • 8.3. Oral
    • 8.3.1. Capsule
    • 8.3.2. Liquid
    • 8.3.3. Tablet
  • 8.4. Transdermal

9. Anxiety Drugs Market, by Patient Type

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Anxiety Drugs Market, by Indication

  • 10.1. Generalized Anxiety Disorder (GAD)
  • 10.2. Obsessive-Compulsive Disorder (OCD)
  • 10.3. Panic Disorder
  • 10.4. Post-Traumatic Stress Disorder (PTSD)
  • 10.5. Social Anxiety Disorder (SAD)

11. Anxiety Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Anxiety Drugs Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Anxiety Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anxiety Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Addex Therapeutics Ltd.
  • 16.3. Amorsa Therapeutics Inc.
  • 16.4. Apotex Inc.
  • 16.5. AstraZeneca PLC
  • 16.6. Avineuro Pharmaceuticals, Inc.
  • 16.7. Azevan Pharmaceuticals, Inc.
  • 16.8. Bausch Health Companies Inc.
  • 16.9. Bionomics Limited
  • 16.10. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • 16.11. Eli Lilly and Company
  • 16.12. F. Hoffmann-La Roche Ltd.
  • 16.13. GlaxoSmithKline PLC
  • 16.14. H. Lundbeck A/S
  • 16.15. Huahai Pharmaceutical Co. Ltd.
  • 16.16. Intra-Cellular Therapies Inc.
  • 16.17. Johnson & Johnson Services Inc.
  • 16.18. Merck & Co., Inc.
  • 16.19. Novartis AG
  • 16.20. Olainfarm
  • 16.21. Otsuka Pharmaceutical Co., Ltd.
  • 16.22. Pfizer Inc.
  • 16.23. Sanofi S.A.
  • 16.24. Sun Pharmaceutical Industries Limited
  • 16.25. Swisschem Healthcare
  • 16.26. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANXIETY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANXIETY DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANXIETY DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANXIETY DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANXIETY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANXIETY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANXIETY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANXIETY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANXIETY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANXIETY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANXIETY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANXIETY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BENZODIAZEPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BENZODIAZEPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BENZODIAZEPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALPRAZOLAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALPRAZOLAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALPRAZOLAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CLONAZEPAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CLONAZEPAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CLONAZEPAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIAZEPAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIAZEPAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIAZEPAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LORAZEPAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LORAZEPAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LORAZEPAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BETA BLOCKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BETA BLOCKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BETA BLOCKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BUSPIRONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BUSPIRONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BUSPIRONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ESCITALOPRAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ESCITALOPRAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ESCITALOPRAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FLUOXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FLUOXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FLUOXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PAROXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PAROXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PAROXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SERTRALINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SERTRALINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SERTRALINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DULOXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DULOXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DULOXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VENLAFAXINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VENLAFAXINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VENLAFAXINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NASAL SPRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NASAL SPRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NASAL SPRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENERALIZED ANXIETY DISORDER (GAD) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENERALIZED ANXIETY DISORDER (GAD) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENERALIZED ANXIETY DISORDER (GAD) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OBSESSIVE-COMPULSIVE DISORDER (OCD) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OBSESSIVE-COMPULSIVE DISORDER (OCD) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OBSESSIVE-COMPULSIVE DISORDER (OCD) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PANIC DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PANIC DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PANIC DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SOCIAL ANXIETY DISORDER (SAD) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SOCIAL ANXIETY DISORDER (SAD) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SOCIAL ANXIETY DISORDER (SAD) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANXIETY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANXIETY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 243. NATO ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL ANXIETY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. FRANCE ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. RUSSIA ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. RUSSIA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 326. RUSSIA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 327. RUSSIA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 328. RUSSIA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 329. RUSSIA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. RUSSIA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 331. RUSSIA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 332. RUSSIA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. RUSSIA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 334. RUSSIA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 335. ITALY ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. ITALY ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 337. ITALY ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 338. ITALY ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 339. ITALY ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 340. ITALY ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 341. ITALY ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 342. ITALY ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 343. ITALY ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. ITALY ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 345. ITALY ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 346. SPAIN ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. SPAIN ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 348. SPAIN ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 349. SPAIN ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 350. SPAIN ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 351. SPAIN ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 352. SPAIN ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 353. SPAIN ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 354. SPAIN ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. SPAIN ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 356. SPAIN ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 357. CHINA ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 358. CHINA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 359. CHINA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 360. CHINA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 361. CHINA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 362. CHINA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 363. CHINA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 364. CHINA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 365. CHINA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 366. CHINA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 367. CHINA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 368. INDIA ANXIETY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 369. INDIA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 370. INDIA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2018-2032 (USD MILLION)
  • TABLE 371. INDIA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2018-2032 (USD MILL